SEC Tracker
Get the app

Medicus Pharma MDCX

Medicus Pharma Q1 FY26: net loss $9.0M; diluted EPS −$0.31

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Medicus Pharma reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$9.0MAgainst −$5.1M in Q1 FY2510-Q income statement, on EDGAR
  2. Diluted EPS−$0.31Against −$0.42 in Q1 FY2510-Q income statement, on EDGAR
  3. Cash and cash equivalents$6.4M+60% from $4.0M in Q1 FY2510-Q balance sheet, on EDGAR
  4. Cash from operations−$9.0MAgainst −$3.9M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Medicus Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Champions Oncology CSBR public float $29M, Oct 31, 2025
  2. OnKure Therapeutics OKUR public float $28M, Jun 30, 2025
  3. Rockwell Medical RMTI public float $29M, Jun 30, 2025
  4. Cumberland Pharmaceuticals CPIX public float $29M, Jun 30, 2025
  5. ProMIS Neurosciences PMN public float $30M, Jun 30, 2025